Tag: priority
Watch out, Merck: FDA grants Regeneron, Sanofi’s Libtayo priority review for...
One month after Regeneron and Sanofi posted impressive data from a phase 3 trial of their PD-1 inhibitor Libtayo in first-line non-small cell lung...
AstraZeneca eyes less-frequent Imfinzi dosing with FDA ‘priority’ boost
Merck’s Keytruda recently became the only member of the PD-1/PD-L1 class with an FDA nod for less-frequent dosing—but AstraZeneca doesn’t intend to let it...
